vs

Side-by-side financial comparison of Accelerant Holdings (ARX) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

Accelerant Holdings is the larger business by last-quarter revenue ($267.4M vs $197.9M, roughly 1.4× REPLIGEN CORP). REPLIGEN CORP runs the higher net margin — 6.7% vs -511.9%, a 518.6% gap on every dollar of revenue.

Accelerant Holdings is a global specialty insurance and reinsurance technology platform that leverages advanced data analytics and risk assessment tools to support insurance carriers, managing general agents, and underwriting partners. It delivers tailored risk solutions, streamlines underwriting workflows, and serves commercial and specialty insurance segments across North America and European markets.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

ARX vs RGEN — Head-to-Head

Bigger by revenue
ARX
ARX
1.4× larger
ARX
$267.4M
$197.9M
RGEN
Higher net margin
RGEN
RGEN
518.6% more per $
RGEN
6.7%
-511.9%
ARX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ARX
ARX
RGEN
RGEN
Revenue
$267.4M
$197.9M
Net Profit
$-1.4B
$13.3M
Gross Margin
52.5%
Operating Margin
-507.7%
9.0%
Net Margin
-511.9%
6.7%
Revenue YoY
13.6%
Net Profit YoY
143.9%
EPS (diluted)
$-6.99
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARX
ARX
RGEN
RGEN
Q4 25
$197.9M
Q3 25
$267.4M
$188.8M
Q2 25
$219.1M
$182.4M
Q1 25
$169.2M
Q4 24
$174.1M
Q3 24
$154.9M
Q2 24
$154.1M
Q1 24
$151.3M
Net Profit
ARX
ARX
RGEN
RGEN
Q4 25
$13.3M
Q3 25
$-1.4B
$14.9M
Q2 25
$8.8M
$14.9M
Q1 25
$5.8M
Q4 24
$-30.3M
Q3 24
$-654.0K
Q2 24
$3.3M
Q1 24
$2.1M
Gross Margin
ARX
ARX
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
ARX
ARX
RGEN
RGEN
Q4 25
9.0%
Q3 25
-507.7%
8.9%
Q2 25
10.2%
7.6%
Q1 25
3.9%
Q4 24
-17.7%
Q3 24
-5.1%
Q2 24
1.0%
Q1 24
1.3%
Net Margin
ARX
ARX
RGEN
RGEN
Q4 25
6.7%
Q3 25
-511.9%
7.9%
Q2 25
4.0%
8.2%
Q1 25
3.4%
Q4 24
-17.4%
Q3 24
-0.4%
Q2 24
2.2%
Q1 24
1.4%
EPS (diluted)
ARX
ARX
RGEN
RGEN
Q4 25
$0.24
Q3 25
$-6.99
$0.26
Q2 25
$0.04
$0.26
Q1 25
$0.10
Q4 24
$-0.55
Q3 24
$-0.01
Q2 24
$0.06
Q1 24
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARX
ARX
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$1.6B
$767.6M
Total DebtLower is stronger
$121.9M
$542.2M
Stockholders' EquityBook value
$676.1M
$2.1B
Total Assets
$7.9B
$2.9B
Debt / EquityLower = less leverage
0.18×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARX
ARX
RGEN
RGEN
Q4 25
$767.6M
Q3 25
$1.6B
$748.7M
Q2 25
$1.4B
$708.9M
Q1 25
$697.2M
Q4 24
$757.4M
Q3 24
$784.0M
Q2 24
$809.1M
Q1 24
$780.6M
Total Debt
ARX
ARX
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$121.9M
$537.9M
Q2 25
$126.7M
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ARX
ARX
RGEN
RGEN
Q4 25
$2.1B
Q3 25
$676.1M
$2.1B
Q2 25
$346.2M
$2.1B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.0B
Q2 24
$2.0B
Q1 24
$2.0B
Total Assets
ARX
ARX
RGEN
RGEN
Q4 25
$2.9B
Q3 25
$7.9B
$2.9B
Q2 25
$7.5B
$2.9B
Q1 25
$2.9B
Q4 24
$2.8B
Q3 24
$2.8B
Q2 24
$2.9B
Q1 24
$2.8B
Debt / Equity
ARX
ARX
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.18×
0.26×
Q2 25
0.37×
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARX
ARX
RGEN
RGEN
Operating Cash FlowLast quarter
$73.9M
$25.7M
Free Cash FlowOCF − Capex
$17.6M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARX
ARX
RGEN
RGEN
Q4 25
$25.7M
Q3 25
$73.9M
$48.1M
Q2 25
$309.3M
$28.6M
Q1 25
$15.0M
Q4 24
$39.2M
Q3 24
$49.3M
Q2 24
$42.2M
Q1 24
$44.7M
Free Cash Flow
ARX
ARX
RGEN
RGEN
Q4 25
$17.6M
Q3 25
$43.4M
Q2 25
$21.5M
Q1 25
$11.4M
Q4 24
$33.6M
Q3 24
$42.3M
Q2 24
$37.4M
Q1 24
$36.4M
FCF Margin
ARX
ARX
RGEN
RGEN
Q4 25
8.9%
Q3 25
23.0%
Q2 25
11.8%
Q1 25
6.8%
Q4 24
19.3%
Q3 24
27.3%
Q2 24
24.3%
Q1 24
24.0%
Capex Intensity
ARX
ARX
RGEN
RGEN
Q4 25
4.1%
Q3 25
2.5%
Q2 25
3.9%
Q1 25
2.1%
Q4 24
3.2%
Q3 24
4.5%
Q2 24
3.1%
Q1 24
5.5%
Cash Conversion
ARX
ARX
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
35.15×
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARX
ARX

Underwriting Segment$117.6M44%
Exchange Services Segment$85.0M32%
Other$64.8M24%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons